Uptake of synthetic Low Density Lipoprotein by leukemic stem cells - A potential stem cell targeted drug delivery strategy

Journal of Controlled Release

Volumn 148, Issue 3, 2010, Pages 380-387

  Zhou, Peixun ^a   Hatziieremia, Sophia ^a   Elliott, Moira A ^b   Scobie, Linda ^c   Crossan, Claire ^c   Michie, Alison M ^a   Holyoake, Tessa L ^a   Halbert, Gavin W ^b   Jørgensen, Heather G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

CD34+; Chronic Myeloid Leukemia; Hemopoietic stem cells; Low Density Lipoprotein; Nanoparticle

Indexed keywords

APOPTOSIS; CD34+; CELL LINES; CHRONIC MYELOID LEUKEMIAS; DRUG CONCENTRATION; HEMOPOIETIC STEM CELLS; IMATINIB; INTRACELLULAR LEVELS; LEUKEMIC CELLS; LOW DENSITY LIPOPROTEINS; PROGENITOR CELL; STEM CELL; TARGETED DRUG DELIVERY;

CELL CULTURE; CELL DEATH; DISEASES; DRUG DELIVERY; NANOPARTICLES;

STEM CELLS;

BCR ABL PROTEIN; CD34 ANTIGEN; LOW DENSITY LIPOPROTEIN; NANOPARTICLE;

ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; INTERNALIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; NEOPLASTIC STEM CELLS;

EID: 78649776870     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.09.016     Document Type: Article

References (39)

1. T.P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M.L. Hensley, I. Gathmann, A.E. Bolton, I.C. van Hoomissen, J.M. Goldman, J.P. Radich, K. Taylor, S. Durrant, A. Schwarer, D. Joske, J. Seymour, A. Grigg, D. Ma, C. Arthur, K. Bradstock, D. Joshua, K. Lechner, G. Verhoef, A. Louwagie, P. Martiat, N. Straetmans, A. Bosly, J. Shepherd, C. Shustik, J. Lipton, D.M. Kovacs, A.R. Turner, J.L. Nielsen, H. Birgens, O.W. Bjerrum, F. Guilhot, J. Reiffers, P. Rousselot, T. Facon, J.L. Harousseau, M. Tulliez, A. Guerci, D. Blaise, F. Maloisel, M. Michallet, T. Fischer, D. Hossfeld, R. Mertelsmann, R. Andreesen, C. Nerl, M. Freund, N. Gattermann, K. Hoeffken, G. Ehninger, M. Deininger, O. Ottmann, C. Peschel, S. Fruehauf, A. Neubauer, P. Le Coutre, W. Aulitzky, M. Baccarani, G. Saglio, R. Fanin, G. Rosti, F. Mandelli, E. Morra, A. Carella, M. Lazzarino, M. Petrini, P.R. Ferrini, F. Nobile, V. Liso, F. Ferrara, V. Rizzoli, G. Fioritoni, G. Martinelli, J. Cornelissen, G. Ossenkoppele, P. Browett, T. Gedde-Dahl, J.M. Tangen, I. Dahl, F. Cervantes, J. Odriozola, J.C.H. Boluda, J.L. Steegmann, C. Canizo, A. Sureda, J. Diaz, A. Granena, M.N. Fernandez, B. Simonsson, L. Stenke, C. Paul, M. Bjoreman, C. Malm, H. Wadenvik, P.G. Nilsson, I. Turesson, A. Gratwohl, U. Hess, M. Solenthaler, S.G. O'Brien, N. Russell, G. Mufti, J. Cavenagh, R.E. Clark, A.R. Green, T.L. Holyoake, G.S. Lucas, G. Smith, D.W. Milligan, S.J. Rule, A.K. Burnett, B.J. Druker, R.A. Larson, R. Moroose, M. Wetzler, J. Bearden, R. Brown, M. Lobell, S. Cataland, I. Rabinowitz, B. Meisenberg, J. Gabrilove, K. Thompson, S. Graziano, P. Emanuel, H. Gross, P. Cobb, R. Bhatia, S. Dakhil, D. Irwin, B. Issell, S. Pavletic, P. Kuebler, E. Layhe, P. Butera, J. Glass, J. Moore, B. Grant, H. Niell, R. Herzig, H. Burris, H. Kantarjian, B. Peterson, B. Powell, M. Kalaycio, D. Stirewalt, W. Samlowski, E. Berman, S. Limentani, T. Seay, T. Shea, L. Akard, P. Becker, S. DeVine, R. Hart, R. Veith, J. Wade, M. Brunvand, R. Silver, I. Kalman, D. Strickland, M. Shurafa, A. Bashey, R. Shadduck, S. Cooper, H. Safah, M. Rubenstein, R. Collins, A. Keller, R. Stone, M. Tallman, D. Stevens, A. Pecora, M. Agha, H. Holmes, and I.S. Grp Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia New England Journal of Medicine 349 2003 1423 1432 (Pubitemid 37211057)
2. A. Hochhaus, S.G. O'Brien, F. Guilhot, B.J. Druker, S. Branford, L. Foroni, J.M. Goldman, M.C. Muller, J.P. Radich, M. Rudoltz, M. Mone, I. Gathmann, T.P. Hughes, R.A. Larson, and I. Investigators Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
3. T. Holyoake, X.Y. Jiang, C. Eaves, and A. Eaves Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia Blood 94 1999 2056 2064
4. S.M. Graham, H.G. Jorgensen, E. Allan, C. Pearson, M.J. Alcorn, L. Richmond, and T.L. Holyoake Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 2002 319 325
5. R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber, M.L. Slovak, and S.J. Forman Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 2003 4701 4707
6. + cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate Leukemia 22 2008 426 428
7. P. Rousselot, F. Huguet, D. Rea, L. Legros, J.M. Cayuela, O. Maarek, O. Blanchet, G. Marit, E. Gluckman, J. Reiffers, M. Gardembas, F.X. Mahon, and M. Intergroupe Francais Leucemies, Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 2007 58 60
8. M. Copland, A. Hamilton, L.J. Eirick, J.W. Baird, E.K. Allan, N. Jordanides, M. Barow, J.C. Mountford, and T.L. Holyoake Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 2006 4532 4539
9. A. Hamilton, L. Elrick, S. Myssina, M. Copland, H. Jorgensen, J.V. Melo, and T. Holyoake BCR-ABL activity and its response to drugs can be determined in CD34(+) CML stem cells by CrkL phosphorylation status using flow cytometry Leukemia 20 2006 1035 1039
10. A. Hamilton, F. Alhashimi, S. Myssina, H.G. Jorgensen, and T.L. Holyoake Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells Experimental Hematology 37 2009 395 401
11. S. Hatziieremia, N.E. Jordanides, T.L. Holyoake, J.C. Mountford, and H.G. Jorgensen Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34(+) cells to imatinib Experimental Hematology 37 2009 692 700
12. R.J. Deckelbaum, G.G. Shipley, and D.M. Small Structure and interactions in human plasma Low Density Lipoprotein Journal of Biological Chemistry 252 1977 744 754
13. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis (Nobel lecture) Angewandte Chemie International Edition in English 25 1986 583 660
14. D. Gal, M. Ohashi, P.C. MacDonald, H.J. Buchsbaum, and E.R. Simpson Low density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms American Journal of Obstetrics and Gynecology 139 1981 877 885
15. S. Vitols, G. Gahrton, Å. Ost, and C.O. Peterson Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation Blood 63 1984 1186 1193
16. V.S. Ghalaut, M.B. Pahwa, Sunita, and P.S. Ghalaut Alteration in lipid profile in patients of chronic myelold leukemia before and after chemotherapy Clinica Chimica Acta 366 2006 239 242
17. L. Tatidis, M. Masquelier, and S. Vitols Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines Biochemical Pharmacology 63 2002 2169 2180
18. S. Hayavi, and G.W. Halbert Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture Biotechnology Progress 21 2005 1262 1268
19. S. Hayavi, G. Baillie, M.D. Owens, and G.W. Halbert Receptor dependent cellular uptake of synthetic low density lipoprotein by mammalian cells in serum-free tissue culture Journal of Pharmacy and Pharmacology 58 2006 1337 1342
20. M.D. Owens, G. Baillie, and G.W. Halbert Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences International Journal of Pharmaceutics 228 2001 109 117
21. G. Baillie, M.D. Owens, and G.W. Halbert A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro Journal of Lipid Research 43 2002 69 73
22. G.W. Halbert, J.F.B. Stuart, and A.T. Florence The incorporation of lipid-soluble antineoplastic agents into microemulsions protein-free analogs of low-density lipoprotein International Journal of Pharmaceutics 21 1984 219 232
23. M. Nikanjam, E.A. Blakely, K.A. Bjornstad, X. Shu, T.F. Budinger, and T.M. Forte Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme International Journal of Pharmaceutics 328 2007 86 94 (Pubitemid 44827556)
24. R.A. Firestone Low-density-lipoprotein as a vehicle for targeting antitumor compounds to cancer-cells Bioconjugate Chemistry 5 1994 105 113
25. J. Stingl, P. Eirew, I. Ricketson, M. Shackleton, F. Vaillant, D. Choi, H.Y.I. Li, and C.J. Eaves Purification and unique properties of mammary epithelial stem cells Nature 439 2006 993 997
26. P.B. Dirks Brain tumor stem cells Biology of Blood and Marrow Transplantation 11 2005 12 13
27. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, and N.J. Maitland Prospective identification of tumorigenic prostate cancer stem cells Cancer Research 65 2005 10946 10951
28. H.G. Jorgensen, E.K. Allan, S.M. Graham, J.L. Godden, L. Richmond, M.A. Elliott, J.C. Mountford, C.J. Eaves, and T.L. Holyoake Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro Leukemia 19 2005 1184 1191
29. W. Kramer, F. Girbig, D. Corsiero, A. Pfenninger, W. Frick, G. Jahne, M. Rhein, W. Wendler, F. Lottspeich, E.O. Hochleitner, E. Orso, and G. Schmitz Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane Journal of Biological Chemistry 280 2005 1306 1320
30. H.G. Jorgensen, E.K. Allan, N.E. Jordanides, J.C. Mountford, and T.L. Holyoake Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34(+) CML cells Blood 109 2007 4016 4019
31. D.L. White, V.A. Saunders, P.O. Dang, J. Engler, A.C.W. Zannettino, A.C. Cambareri, S.R. Quinn, P.W. Manley, and T.P. Hughes OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 2006 697 704
32. D.L. White, V.A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P.W. Manley, and T. Hughes Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood 110 2007 4064 4072
33. N.E. Jordanides, H.G. Jorgensen, T.L. Holyoake, and J.C. Mountford Functional ABCG2 is overexpressed on primary CML CD34(+) cells and is inhibited by imatinib mesylate Blood 108 2006 1370 1373
34. A. Davies, N.E. Jordanides, A. Giannoudis, C.M. Lucas, S. Hatziieremia, R.J. Harris, H.G. Jorgensen, T.L. Holyoake, M. Pirmohamed, R.E. Clark, and J.C. Mountford Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters Leukemia 23 2009 1999 2006
35. E. Weisberg, P.W. Manley, W. Breitenstein, J. Bruggen, S.W. Cowan-Jacob, A. Ray, B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, A.L. Kung, J. Mestan, G.Q. Daley, L. Callahan, L. Catley, C. Cavazzall, M. Azam, D. Neuberg, R.D. Wright, G. Gilliland, and J.D. Griffin Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
36. Y.K. Ho, R.G. Smith, M.S. Brown, and J.L. Goldstein Low-density lioprotein (LDL) receptor activity in human acute myelogenous leukaemia cells Blood 52 1978 1099 1104
37. M. Nikanjam, A.R. Gibbs, A. Hunt, T.F. Budinger, and T.M. Forte Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme Journal of Controlled Release 124 2007 163 171 (Pubitemid 350101886)
38. C. Bellodi, M.R. Lidonnici, A. Hamilton, G.V. Helgason, A.R. Soliera, M. Ronchetti, S. Galavotti, K.W. Young, T. Selmi, R. Yacobi, R.A. Van Etten, N. Donato, A. Hunter, D. Dinsdale, E. Tirro, P. Vigneri, P. Nicotera, M.J. Dyer, T. Holyoake, P. Salomoni, and B. Calabretta Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells Journal of Clinical Investigation 119 2009 1109 1123
39. J. WilsonRawls, S.H. Xie, J.X. Liu, P. Laneuville, and R.B. Arlinghaus P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation Cancer Research 56 1996 3426 3430